Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone (LadyDe)
Oocyte Donors, Oocyte Donation

About this trial
This is an interventional treatment trial for Oocyte Donors focused on measuring cumulus-oocyte complexes, progestin primed ovarian stimulation, controlled ovarian stimulation, luteal phase ovarian stimulation, follicular phase ovarian stimulation, follitropin delta, dydrogesterone
Eligibility Criteria
Inclusion Criteria:
- Body mass Index (BMI) ≥18 to < 28
- Signed informed consent
- Regular menstrual cycle length i.e. 24-35 days
Exclusion Criteria:
- Contraindications to the use of gonadotropins
- Endometriosis grade 3-4
- Patients with Anti-mullerian hormone (AMH) <1.1 ng/ml and/or antral follicular count (AFC)<7
- Patients with Follicle Number Per Ovary (FNPO) ≥ 19 and/or AMH >5ng/ml
- Patients under contraception with hormonal intrauterine device (IUD)
- Any untreated endocrine abnormality
Sites / Locations
- Brussels IvfRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
Follitropin delta and dydrogesterone (treatment A followed by treatment B)
Follitropin delta and dydrogesterone (treatment B followed by treatment A)
Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved. Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH > 10 IU/L until day of trigger. For both treatment (A and B) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles >20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated.
Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH > 10 IU/L until day of trigger. Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta12 mcg/daily (Rekovelle) from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved. For both treatment (B and A) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles >20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated.